31.05.2008 – 18:32

/K I L L K I L L K I L L -- Merck Serono/

We are advised by Merck Serono that journalists and other readers
should  disregard the news release "Erbitux Significantly Prolongs
Survival in  1st-Line Treatment of Non-Small Cell Lung Cancer"
NYSE:SRA, issued today  due to premature release. This release will
be reissued at a later date.

Contact:

Contact: Dr. Raphaela Farrenkopf, Phone +49-6151-72-2274

Plus de actualités: Merck Serono

Tous Actualités Tous

31.05.2008 – 16:02
Erbitux Significantly Prolongs Survival in 1st-Line Treatment of Non-Small Cell Lung Cancer
Chicago and Darmstadt, Germany (ots/PRNewswire) - - New Data Provides the Basis for the Future Role of Erbitux (cetuximab) as a Standard in Combination With Platinum-Based Chemotherapy in the 1st-Line Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) - Location: Annual Meeting of the American Society of Clinical Oncology (ASCO) 2008, Chicago, ...
plus

Ces informations peuvent également vous intéresser

/K I L L K I L L K I L L -- Merck Serono/

Enterprises

Économie

Erbitux Significantly Prolongs Survival in 1st-Line Treatment of Non-Small Cell Lung Cancer